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Introduction
The advent of biologic medications has considerably
increased the potential for treatment benefit in juvenile
idiopathic arthritis (JIA), with clinical remission being now
achievable in a substantial proportion of patients.
Objectives
To evaluate the outcome of etanercept (ETN) therapy in
Italian children with JIA.
Methods
This is a multicenter, observational study that includes all
children with JIA who were given ETN at Italian pediatric
rheumatology centers after January 2000. Patients were
classified in 2 groups: Group 1: patients who were no
longer taking ETN at study start; Group 2: patients who
were still receiving ETN at study start. Patients in Group 1
underwent only retrospective assessments, whereas
patients in Group 2 underwent both retrospective and
cross-sectional assessments. The primary outcome of the
study were reasons for ETN discontinuation in patients in
Group 1, and achievement of the states of inactive disease
(ID), minimal disease activity (MDA) and parent- and
child-acceptable symptom state (PASS, CASS) in patients
in Group 2. The above states were assessed through both
formal definitions and JADAS cutoffs. The secondary
outcome was the evaluation of frequency and characteris-
tics of ETN-related side effects.
Results
Twenty-five centers were asked to make a census of all
patients followed at the center who met the inclusion
criteria for Group 1 or Group 2. A total of 1230 patients
were included in the census. Of these patients, 624 were
still receiving ETN (Group 2), whereas 606 had discontin-
ued ETN (Group 1). So far, the data of 772 patients
(448 in Group 1 and 324 in Group 2) have been collected.
Among the 448 patients in Group 1, reasons for ETN dis-
continuation included disease remission (57.1%), lack of
efficacy (25.5%), and side effects (14.9%). The results of
assessment of disease state through formal definitions in
305 children of the 324 children in Group 2 who had
already undergone the cross-sectional evaluation were the
following: ID 42.2%, MDA 63.8%, PASS 80.9%, CASS
76.7%. The percentages of patients who reached the same
disease states assessed through JADAS cutoffs were: ID
45.7%, MDA 62.5%, PASS 71.1%, CASS 67.4%. Serious
adverse events were seen in 10 of the 772 patients and
included inflammatory bowel disease (4 pts), tuberculosis
(1 pt), CMV hepatitis (1 pt), varicella complicated by
bronchopneumonia (1 pt), bladder carcinoma (1pt), thyr-
oid carcinoma (1 pt); 1 patient died of streptococcal sepsis.
1Istituto G Gaslini, Genova, Italy
Full list of author information is available at the end of the article
Verazza et al. Pediatric Rheumatology 2014, 12(Suppl 1):P130
http://www.ped-rheum.com/content/12/S1/P130
© 2014 Verazza et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Conclusion
A substantial proportion of children currently receiving
ETN were in the states of ID or MDA, or were satisfied
with treatment outcome. More than half of the patients
who had been discontinued from ETN before study start
had the medication stopped because of disease remission.
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